30 closest matches · ranked by relevance
AIDS-Related-Primary Central Nervous System Lymphoma
Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants
Lymphoma
Primary: Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or…
AIDS-related Diffuse Large Cell Lymphoma · AIDS-related Diffuse Mixed Cell Lymphoma · AIDS-related Diffuse Small Cleaved Cell Lymphoma
Primary: Overall Survival — 0; 0 Proportion of participants
Lymphoma, AIDS-related · Lymphoma, Large B-Cell, Diffuse
Primary: Median Progression Free Survival (PFS) — 13.8 years
AIDS-related Diffuse Large Cell Lymphoma · AIDS-related Immunoblastic Large Cell Lymphoma · AIDS-related Peripheral/Systemic Lymphoma
Primary: Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment — 0.69; 0.53 proportion
AIDS-Related Kaposi Sarcoma · Recurrent Kaposi Sarcoma
Primary: Maximum Tolerated Dose of Lenalidomide Defined as the Dose Level at Which 0/6 or 1/6 Subjects Experience Dose Limiting Toxicity (DLT) With the Next Higher Dose Having at…
Lymphoma
Primary: Overall Survival (OS) at 1 Year — 1.0; 0.82 Cumulative proportion surviving at 1 yr
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Lymphoma, T-Cell · Lymphoma, Extranodal NK-T-Cell
Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab — 30 mg
AIDS-Related Plasmablastic Lymphoma · AIDS-Related Primary Effusion Lymphoma · Ann Arbor Stage I Diffuse Large B-Cell Lymphoma
Primary: Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II) — 67.5; 76.2 percentage of participants
AIDS-Related Hodgkin Lymphoma · Ann Arbor Stage II Hodgkin Lymphoma · Ann Arbor Stage IIA Hodgkin Lymphoma
Primary: Maximal Tolerated Dose of Brentuximab Vedotin (Phase I) — 1.2 mg/kg
Lymphoma
Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants
Leukemia-Lymphoma, Adult T-Cell
Primary: Tolerability of Treatment as Measured by Number of Participants With Grade 3 or Higher Adverse Events — 1; 1; 1; 2 participants
Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Extranodal Marginal Zone Lymphoma
Primary: Relapse-free Survival (RFS) — 83 months
Brain and Central Nervous System Tumors · Lymphoma
Primary: Number of Phase I Participants Experiencing Toxicity — 1; 3 Participants
Relapsed or Refractory EBV-and CD30-positive Lymphomas
Primary: To Evaluate the Overall Response Rate (ORR) of Brentuximab Vedotin in EBV- and CD30-positive Lymphomas — 12 Participants
Diffuse Large B-Cell Lymphoma (DLBCL) · Primary Mediastinal Large B-cell Lymphoma · Burkitt Lymphoma
Primary: Overall Response (Complete Response + Partial Response) — 216; 94 Participants
Lymphoma
Primary: Toxicity as Assessed by NCI CTCAE v3.0 (Phase I) — 3; 3; 5; 2 Participants
Lymphoma
Primary: Complete Response Rate at 20 Weeks — 45 percentage of participants
Lymphoma, Non-Hodgkin
Primary: Number of Participants With Confirmed Response, Including Participants With Complete Response (CR), Clinical Complete Response (CCR), and Partial Response (PR) — 72…
Primary Mediastinal B-cell Lymphoma · Diffuse, Large B-cell Lymphoma · Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma
Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants
Chemotherapeutic Agent Toxicity · Cognitive/Functional Effects · Lymphoma
Primary: Progression-free Survival — 2.1; NA years — p=0.015
Non-Hodgkin's Lymphoma · CNS Lymphoma
Primary: Proportion of Patients With CNS Involvement by B-cell NHL, Relapsed PCNSL, or Relapsed PIOL Who Are Alive and Progression-free at One Year — 28 Participants
Lymphoma
Primary: Progression-free Survival — 89 percentage of participants
Lymphoma
Primary: Overall Response Rate (ORR) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen — 100; 100; 100; 100 percentage of patients
Central Nervous System Lymphoma
Primary: Complete Remission Rate After Primary Chemotherapy — 23; 30; 49 Percentage of participants
Hodgkin Lymphoma · Diffuse Large B-Cell Lymphoma
Primary: Progression Free Survival (PFS) — 6.6 months
Lymphoma
Primary: Percentage of Participants With 3-year Progression-free Survival (PFS) — 90 percentage of participants